PPARs and LXRs: atherosclerosis goes nuclear.
Atherosclerosis is the leading cause of mortality in the Western world, and new therapeutics to target the metabolic and inflammatory factors that underlie its pathogenesis are needed. Peroxisome proliferator-activated receptors and liver X receptors are lipid-activated nuclear receptors that regulate systemic glucose and lipid metabolism, and modulate inflammation within the vascular wall. New understanding of their functions in physiology and the development of high-affinity synthetic ligands highlight their potential as targets for the treatment of cardiovascular disease.
Barish
Grant D
GD
Howard Hughes Medical Institute, Gene Expression Laboratory, The Salk Institute for Biological Studies, PO Box 85800, San Diego, CA 92186-5800, USA.
Evans
Ronald M
RM
D000818:Animals; D004268:DNA-Binding Proteins; D006801:Humans; D007536:Isomerism; D000071518:Liver X Receptors; D057093:Orphan Nuclear Receptors; D047492:Peroxisome Proliferator-Activated Receptors / Q000502:physiology*; D018160:Receptors, Cytoplasmic and Nuclear / Q000502:physiology*; D015398:Signal Transduction / Q000502:physiology
D004268:DNA-Binding Proteins; D000071518:Liver X Receptors; D057093:Orphan Nuclear Receptors; D047492:Peroxisome Proliferator-Activated Receptors; D018160:Receptors, Cytoplasmic and Nuclear